RxDoctor Payments Data

Scott Piette, DO

Glaucoma Specialist · East Lansing, MINPI 1861423899

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,500 of the $44,558 with a category attached, or 64.0%. AbbVie accounts for 93.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $11,188 and has fallen 95.8% since, to $475 in 2025.

$44,558in general payments, 2019–2025

Across 245 payments — averaging $181.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$42K
  • Sight Sciences, Inc.$546
  • Glaukos Corporation$357
  • Sun Pharmaceutical Industries Inc.$294
  • Alcon$293
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$270
  • plus $1K from 14 others
$220,055in research payments, 2019–2025

Across 68 payments — averaging $3236.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$218K
  • Glaukos Corporation$2K

What the payments were for

  • Consulting fees$3,0007%
  • Speaking & faculty fees$28,50064%
  • Travel & lodging$7,26116%
  • Food & beverage$5,77613%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$410,512
Medicare patients
1,065
Services billed
4,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost286$125,656
RestasisCyclosporine57$58,716
Alphagan PBrimonidine Tartrate123$34,187
SimbrinzaBrinzolamide/Brimonidine Tart94$29,099
VyzultaLatanoprostene Bunod48$20,543
ProlensaBromfenac Sodium55$19,871
RocklatanNetarsudil Mesylat/Latanoprost46$16,753
Prednisolone Acetate341$16,262
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol121$16,251
CombiganBrimonidine Tartrate/Timolol34$15,686
Brimonidine Tartrate362$13,939
XiidraLifitegrast12$12,126
Latanoprost1,331$11,997
RhopressaNetarsudil Mesylate16$8,330
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat639$8,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$41,776$234,245500 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$15$32,66960 claims
AlconSimbrinza$293$29,09994 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$233$25,08262 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$270$22,90067 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in East Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →